Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation
M Yu, M Liu, W Zhang, Y Ming - Current drug metabolism, 2018 - ingentaconnect.com
Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …
immunosuppressant which consists of the footstone as immunosuppressive regimens in …
Relevance of genetic polymorphisms of the human cytochrome P450 3A4 in rivaroxaban-treated patients
MF Ercisli, G Lechun, SH Azeez… - Cellular, Molecular …, 2021 - cmbr-journal.com
Rivaroxaban is an anticoagulant drug that prevents forming of blood clots. In addition, it can
be administered to prevent and treat thrombotic diseases such as atrial fibrillation, cardiac …
be administered to prevent and treat thrombotic diseases such as atrial fibrillation, cardiac …
Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives
AL Degraeve, S Moudio, V Haufroid… - Expert opinion on …, 2020 - Taylor & Francis
Introduction In kidney transplantation, tacrolimus (TAC) is at the cornerstone of current
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …
[HTML][HTML] Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles
WS Oetting, DP Schladt, W Guan, MB Miller… - American Journal of …, 2016 - Elsevier
We previously reported that tacrolimus (TAC) trough blood concentrations for African
American (AA) kidney allograft recipients were lower than those observed in white patients …
American (AA) kidney allograft recipients were lower than those observed in white patients …
The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian …
WS Oetting, B Wu, DP Schladt, W Guan… - The …, 2018 - nature.com
The immunosuppressant tacrolimus (TAC) is metabolized by both cytochrome P450 3A4
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …
[HTML][HTML] CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
M Déri, Z Szakál-Tóth, F Fekete, K Mangó, E Incze… - Scientific Reports, 2021 - nature.com
High inter-individual variability in tacrolimus clearance is attributed to genetic
polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by …
polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by …
The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients
J Sachau, H Bruckmueller… - … Journal of Pain, 2021 - Wiley Online Library
Background The serotonin receptor 2A (HTR2A) has been described as an important
facilitation mediator of spinal nociceptive processing leading to central sensitization (CS) in …
facilitation mediator of spinal nociceptive processing leading to central sensitization (CS) in …
[HTML][HTML] CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
T Majam, C Sukasem, T Reungwetwattana… - Frontiers in …, 2023 - frontiersin.org
Background: Osimertinib has shown greater efficacy than standard epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug …
receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug …
[HTML][HTML] CYP3A5 and UGT1A9 polymorphisms influence immunosuppressive therapy in pediatric kidney transplant recipients
Background: Tacrolimus (TAC) and mycophenolic acid (MPA) are the main
immunosuppressive drugs used in pediatric kidney transplantation. Single nucleotide …
immunosuppressive drugs used in pediatric kidney transplantation. Single nucleotide …